Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Potentially Inappropriate Medications for Adults Below 65 Years: Protocol for a Modified Delphi Study.

JMIR research protocols·2026
Same author

Extension of the Consolidated Criteria for Reporting Qualitative Research Guideline to Large Language Models (COREQ+LLM): Protocol for a Multiphase Study.

JMIR research protocols·2025
Same author

The Prevalence of Potentially Inappropriate Medication in Geriatric Inpatients According to the PRISCUS 2.0 List.

Deutsches Arzteblatt international·2023
Same author

In Reply.

Deutsches Arzteblatt international·2023
Same author

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults.

Scientific reports·2023
Same author

[Polypharmacy in nursing homes: options to improve drug therapy safety].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2023

Related Experiment Video

Updated: Jul 11, 2026

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways
10:44

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways

Published on: December 9, 2013

[Sex-specific differences in drug treatment].

Petra A Thürmann1

  • 1Philipp Klee-Institut für Klinische Pharmakologie, HELIOS Klinikum Wuppertal, Lehrstuhl für Klinische Pharmakologie, Universität Witten/Herdecke, Germany. petra.thuermann@helios-kliniken.de

Therapeutische Umschau. Revue Therapeutique
|September 20, 2007
PubMed
Summary

Women experience more adverse drug reactions than men due to significant sex-related differences in drug metabolism and cardiac electrophysiology. This highlights the need for gender-specific therapies and clinical trial considerations.

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Experiment Videos

Last Updated: Jul 11, 2026

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways
10:44

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways

Published on: December 9, 2013

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Area of Science:

  • Pharmacology and Toxicology
  • Clinical Trial Design
  • Pharmacogenetics

Context:

  • Historical exclusion of women from clinical trials post-thalidomide.
  • Growing evidence of sex-based differences in drug pharmacokinetics and pharmacodynamics.
  • Underrepresentation of women in research leading to potential therapeutic disparities.

Purpose:

  • To review and highlight significant sex-related differences in drug response and adverse events.
  • To emphasize the clinical relevance of gender-specific variations in drug metabolism and cardiac electrophysiology.
  • To advocate for gender-specific approaches in drug development and clinical practice.

Summary:

  • Significant sex differences exist in drug metabolism (e.g., cytochrome P450 enzymes, glucuronidation) and receptor interactions (e.g., opiates, benzodiazepines).
  • Women exhibit a higher susceptibility to drug-induced QT-prolongation and Torsades de Pointes arrhythmia.
  • Gender-specific symptoms in conditions like depression and heart failure warrant tailored therapeutic strategies.

Impact:

  • Informs the need for increased inclusion of women in clinical trials.
  • Supports the development of personalized medicine considering sex as a biological variable.
  • Aims to improve drug safety and efficacy by addressing gender-specific responses to medications.